Global Penny Stocks With Market Caps Over US$300M

As global markets navigate a complex landscape marked by cautious Federal Reserve commentary and steady inflation rates, investors are reassessing their strategies. In such times, identifying stocks with solid fundamentals becomes crucial, especially when considering penny stocks—an investment area that continues to hold potential despite its somewhat outdated label. These smaller or newer companies can offer unique opportunities for growth and value, as we'll explore through three examples of penny stocks that demonstrate financial strength and promise in today's market conditions.

Top 10 Penny Stocks Globally

Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.52 HK$940.15M ★★★★★★ IVE Group (ASX:IGL) A$2.80 A$433.4M ★★★★★☆ HSS Engineers Berhad (KLSE:HSSEB) MYR0.645 MYR327.97M ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.55 HK$2.12B ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ Deleum Berhad (KLSE:DELEUM) MYR1.37 MYR550.13M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD3.37 SGD13.26B ★★★★★☆ Integrated Diagnostics Holdings (LSE:IDHC) $0.545 $316.82M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.16 £184.68M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.055 €284.04M ★★★★★★

Click here to see the full list of 3,727 stocks from our Global Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Liuzhou Chemical Industry

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Liuzhou Chemical Industry Co., Ltd. is a Chinese company that produces and sells hydrogen peroxide, with a market capitalization of approximately CN¥2.91 billion.

Operations: The company generates its revenue of CN¥159.42 million from the chemical industry segment.

Market Cap: CN¥2.91B

Liuzhou Chemical Industry Co., Ltd. presents a mixed picture for investors interested in penny stocks. The company is debt-free, with short-term assets of CN¥501.5 million comfortably exceeding liabilities, indicating strong financial positioning. However, recent earnings have declined sharply, with net income dropping to CN¥3.44 million from CN¥15.65 million year-over-year due to a large one-off loss and decreased profit margins from 54.5% to 11.3%. Despite stable weekly volatility and an experienced management team averaging 7.8 years tenure, the negative earnings growth over the past year raises concerns about its future profitability trajectory within the chemicals industry.

Jump into the full analysis health report here for a deeper understanding of Liuzhou Chemical Industry. Assess Liuzhou Chemical Industry's previous results with our detailed historical performance reports.

Story Continues

SHSE:600423 Debt to Equity History and Analysis as at Oct 2025

Huapont Life SciencesLtd

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Huapont Life Sciences Co., Ltd. operates in the fields of medicine, medical care, agrochemicals, new materials, and tourism both in China and internationally with a market capitalization of CN¥8.98 billion.

Operations: The company generates revenue from two primary segments: CN¥8.14 billion from China and CN¥3.55 billion from overseas markets.

Market Cap: CN¥8.98B

Huapont Life Sciences Co., Ltd. offers a complex scenario for penny stock investors. Despite being unprofitable with declining earnings over the past five years, it has managed to stabilize its weekly volatility at 4% and reduce its debt-to-equity ratio from 90.6% to 55.6%. The company's short-term assets of CN¥11.5 billion exceed both short-term and long-term liabilities, indicating solid liquidity management. Recent earnings show an increase in net income to CN¥388.46 million for H1 2025, compared to CN¥313.52 million the previous year, yet dividends remain unsustainable due to insufficient earnings coverage despite shareholder approval for interim profit distribution plans.

Take a closer look at Huapont Life SciencesLtd's potential here in our financial health report. Gain insights into Huapont Life SciencesLtd's historical outcomes by reviewing our past performance report.SZSE:002004 Financial Position Analysis as at Oct 2025

Jiangsu Skyray Instrument

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Jiangsu Skyray Instrument Co., Ltd. specializes in providing instruments for spectroscopy and chromatography, with a market cap of CN¥2.30 billion.

Operations: Revenue segments for Jiangsu Skyray Instrument Co., Ltd. are not reported.

Market Cap: CN¥2.3B

Jiangsu Skyray Instrument Co., Ltd. presents a mixed picture for penny stock investors. The company remains unprofitable, with losses increasing at 41.7% annually over the past five years and a negative return on equity of -7.85%. Despite this, it maintains a sufficient cash runway for more than three years due to positive free cash flow and has not significantly diluted shareholders recently. Its short-term assets of CN¥3 billion cover both short-term and long-term liabilities, indicating strong liquidity management despite high net debt to equity ratio of 89.5%. Recent bylaw amendments suggest potential strategic shifts ahead.

Click here to discover the nuances of Jiangsu Skyray Instrument with our detailed analytical financial health report. Learn about Jiangsu Skyray Instrument's historical performance here.SZSE:300165 Financial Position Analysis as at Oct 2025

Where To Now?

Click this link to deep-dive into the 3,727 companies within our Global Penny Stocks screener. Contemplating Other Strategies? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SHSE:600423 SZSE:002004 and SZSE:300165.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments